Search All UT System Experts

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

Mario Campone, Seock Ah Im, Hiroji Iwata, Mark Clemons, Yoshinori Ito, Ahmad Awada, Stephen Chia, Agnieszka Jagiełło-Gruszfeld, Barbara Pistilli, Ling Ming Tseng, Sara Hurvitz, Norikazu Masuda, Javier Cortés, Michele De Laurentiis, Carlos L. Arteaga, Zefei Jiang, Walter Jonat, Sylvie Le Mouhaër, Banu Sankaran, Laurence BourdeauMona El-Hashimy, Dalila Sellami, José Baselga

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Fingerprint

Dive into the research topics of 'Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2'. Together they form a unique fingerprint.

Medicine & Life Sciences